About +
Our Story
Meet the Team
Inhaled Interferon β +
Our Programmes
Publications
Investors +
Share Price Information
Reports & Presentations
Investor News
Shareholder Information
AIM Rule 26
Corporate Governance
News +
Press Releases & Media
TR-1/Options Press Releases
Careers
Contact
About
Inhaled Interferon β
Investors
News
Careers
Contact
Back
Our Story
Meet the Team
Back
Our Programmes
Publications
Back
Share Price Information
Reports & Presentations
Investor News
Shareholder Information
AIM Rule 26
Corporate Governance
Back
Press Releases & Media
TR-1/Options Press Releases
Media
Read our latest news and download information and resources.
Featured News
Full Year Results
Synairgen presents at ATS 2022
Presentation at ECCMID
In the News
Discover all mentions
WebMD's John Whyte MD talks to Synairgen CEO Richard Marsden
Synairgen founder Professor Sir Stephen Holgate talks to John Whyte MD of WebMD
Synairgen presents data on antiviral activity of lead asset
Press
View all press releases
Subscribe to news
2022
Full Year Results
25th May 2022
Synairgen presents at ATS 2022
16th May 2022
Presentation at ECCMID
25th April 2022
Synairgen to present at ATS 2022
5th April 2022
Synairgen provides update on ACTIV-2 Trial
17th March 2022
Update on SNG001
3rd March 2022
Topline results from Phase 3 SPRINTER trial
21st February 2022
Synairgen announces partnership with Ashfield Engage
6th January 2022
2021
ESWI presentation demonstrates interferon beta has potent antiviral activity against SARS-CoV-2 including variants of concern
8th December 2021
Synairgen presents SNG001 data at ESWI
6th December 2021
